CANCER:

Endometrial Adenocarcinoma

Related cancers:

‹

Endometrial Cancer (164)

Endometrial Cancer (164)

›

HER-2 expression HER-2 expression	Endometrial Adenocarcinoma Endometrial Adenocarcinoma	trastuzumab Sensitive: A2 - Guideline
HER-2 overexpression HER-2 overexpression	Endometrial Adenocarcinoma Endometrial Adenocarcinoma	trastuzumab Sensitive: C1 - Off-label
HER-2 positive HER-2 positive	Endometrial Adenocarcinoma Endometrial Adenocarcinoma	trastuzumab Sensitive: C1 - Off-label
MSI-H/dMMR MSI-H/dMMR	Endometrial Adenocarcinoma Endometrial Adenocarcinoma	AZD1775 Sensitive: C3 – Early Trials
HER-2 positive HER-2 positive	Endometrial Adenocarcinoma Endometrial Adenocarcinoma	trastuzumab Sensitive: C3 – Early Trials
ER positive ER positive	Endometrial Adenocarcinoma Endometrial Adenocarcinoma	letrozole + zoledronic acid Sensitive: C4 – Case Studies
MSH6 F1088fs MSH6 F1088fs	Endometrial Adenocarcinoma Endometrial Adenocarcinoma	pembrolizumab Sensitive: C4 – Case Studies
HER-2 amplification HER-2 amplification	Endometrial Adenocarcinoma Endometrial Adenocarcinoma	lapatinib Sensitive: D – Preclinical
HER-2 amplification HER-2 amplification	Endometrial Adenocarcinoma Endometrial Adenocarcinoma	trastuzumab + lapatinib Sensitive: D – Preclinical
HER-2 amplification HER-2 amplification	Endometrial Adenocarcinoma Endometrial Adenocarcinoma	afatinib Sensitive: D – Preclinical